Disagree with your analysis, when considering the discrepancy between US and AUS vehicles.
When reviewing the AUS data alone, the primary endpoint data is statistically significant for inflammatory lesions.
IF there had been no discrepancy, your analysis would stand.
Unfortunately, the data is the data and BOT cannot discredit the US results (at this stage anyway), however they have clearly undertaken a root cause analysis and put a plan in motion to resolve for phase 3.
Cheers,
Sven
Disagree with your analysis, when considering the discrepancy...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.3¢ |
Change
-0.018(4.61%) |
Mkt cap ! $660.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $2.289M | 6.300M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 538981 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 146378 | 11 |
View Market Depth
| Last trade - 12.19pm 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |